Literature DB >> 23263823

Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer.

Patricia A Tang1, Daniel Y C Heng.   

Abstract

Programmed death 1 (PD-1) is a T cell co-inhibitory receptor with two ligands, PD-L1 and PD-L2. In cancer, this pathway plays a major role in immune resistance in the tumor environment. Blockade of this pathway can enhance antitumor immune responses. This review discusses the preclinical rationale for PD-1 pathway inhibition in advanced renal cell carcinoma and prostate cancer, in addition to the clinical activity and toxicity of the anti-PD-L1 antibody BMS-936559, as well as anti-PD-1 antibodies MK-3475 and BMS-936558.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23263823     DOI： 10.1007/s11912-012-0284-2

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  44 in total

1.  Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.

Authors:  Benedetto Farsaci; Jack P Higgins; James W Hodge
Journal:  Int J Cancer       Date:  2011-08-08       Impact factor: 7.396

2.  Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens.

Authors:  Mohammad I Zia; Lillian L Siu; Greg R Pond; Eric X Chen
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

3.  Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma.

Authors:  Xavier Frigola; Brant A Inman; Christine M Lohse; Christopher J Krco; John C Cheville; R Houston Thompson; Bradley Leibovich; Michael L Blute; Haidong Dong; Eugene D Kwon
Journal:  Clin Cancer Res       Date:  2011-02-25       Impact factor: 12.531

Review 4.  Cancer immunotherapy comes of age.

Authors:  Suzanne L Topalian; George J Weiner; Drew M Pardoll
Journal:  J Clin Oncol       Date:  2011-10-31       Impact factor: 44.544

5.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

6.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

7.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

Authors:  R Houston Thompson; Susan M Kuntz; Bradley C Leibovich; Haidong Dong; Christine M Lohse; W Scott Webster; Shomik Sengupta; Igor Frank; Alexander S Parker; Horst Zincke; Michael L Blute; Thomas J Sebo; John C Cheville; Eugene D Kwon
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

8.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

Authors:  Junko Ozao-Choy; Ge Ma; Johnny Kao; George X Wang; Marcia Meseck; Max Sung; Myron Schwartz; Celia M Divino; Ping-Ying Pan; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

9.  Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters.

Authors:  Kathleen Ebelt; Gregor Babaryka; Bernhard Frankenberger; Christian G Stief; Wolfgang Eisenmenger; Thomas Kirchner; Dolores J Schendel; Elfriede Noessner
Journal:  Eur J Cancer       Date:  2009-03-21       Impact factor: 9.162

10.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598
View more
  18 in total

1.  Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?

Authors:  Mahmoud Abbas; Sandra Steffens; Maria Bellut; Jan U Becker; Anika Großhennig; Hendrik Eggers; Gerd Wegener; Markus A Kuczyk; Hans H Kreipe; Viktor Grünwald; Andres J Schrader; Philipp Ivanyi
Journal:  Med Oncol       Date:  2016-05-10       Impact factor: 3.064

2.  PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection.

Authors:  Alexander W MacFarlane; Mowafaq Jillab; Elizabeth R Plimack; Gary R Hudes; Robert G Uzzo; Samuel Litwin; Essel Dulaimi; Tahseen Al-Saleem; Kerry S Campbell
Journal:  Cancer Immunol Res       Date:  2013-11-25       Impact factor: 11.151

Review 3.  Pembrolizumab: first global approval.

Authors:  Raewyn M Poole
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

Review 4.  Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design.

Authors:  Sitanshu S Singh; Seetharama D Jois
Journal:  Adv Protein Chem Struct Biol       Date:  2017-10-06       Impact factor: 3.507

5.  Pan-cancer analysis of TCGA data reveals notable signaling pathways.

Authors:  Richard Neapolitan; Curt M Horvath; Xia Jiang
Journal:  BMC Cancer       Date:  2015-07-14       Impact factor: 4.430

Review 6.  Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.

Authors:  Victoria Hillerdal; Magnus Essand
Journal:  BioDrugs       Date:  2015-04       Impact factor: 5.807

Review 7.  Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.

Authors:  Maxine Bauzon; Terry Hermiston
Journal:  Front Immunol       Date:  2014-02-24       Impact factor: 7.561

Review 8.  Novel immunotherapies in GU malignancies.

Authors:  Alexandra Drakaki; David F McDermott
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.945

9.  Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation.

Authors:  Dagmar Quandt; Simon Jasinski-Bergner; Ulrike Müller; Bianca Schulze; Barbara Seliger
Journal:  J Transl Med       Date:  2014-05-30       Impact factor: 5.531

10.  Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis.

Authors:  Ran Chen; Pei-Chun Peng; Bin Wen; Fu-Ying Li; Sheng Xie; Guozhong Chen; Jiefu Lu; Zhuoyu Peng; Shao-Bo Tang; Yu-Mei Liang; Xin Deng
Journal:  Transl Oncol       Date:  2016-02       Impact factor: 4.243
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.